Titan Pharmaceuticals and Braeburn Pharmaceuticals Announce Date of FDA Advisory Committee Review of Probuphine for Opioid Addiction December 9, 2015
Titan Pharmaceuticals Adds ProNeura Implant for Hypothyroidism to Product Development Pipeline November 16, 2015
Titan Pharmaceuticals Schedules Conference Call to Review Third Quarter 2015 Financial Results November 10, 2015
Titan Pharmaceuticals Provides Opinion of Counsel Covering Issuance and Resale of Shares Underlying Public Warrants October 7, 2015
Titan Pharmaceuticals Announces FDA's Acceptance of Resubmission of New Drug Application for Probuphine September 28, 2015
Titan Pharmaceuticals to Present at Rodman & Renshaw 17th Annual Global Investment Conference September 3, 2015
Titan Pharmaceuticals Announces Resubmission of the New Drug Application for Probuphine for the Maintenance Treatment of Opioid Addiction August 31, 2015
